(thirdQuint)Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa Versus Individual Administration of Each Vaccine.

 Multicentre study with 4 parallel groups.

 One group will receive GSK134612 co-administered with Infanrix hexa cent , two groups will receive sequential administration of GSK134612 and Infanrix hexa cent and the final group will receive Meningitec cent .

 For subjects in Groups B and C, three blood samples will be taken: prior to first vaccination and 1 month after each vaccination.

 For subjects in Groups A and D, two blood samples will be taken: prior to and 1 month after vaccination.

.

 Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa Versus Individual Administration of Each Vaccine@highlight

The purpose of this study is to demonstrate, in 12-23 months old subjects, the non-inferiority of meningococcal vaccine GSK134612 co-administered with Infanrix hexa cent , compared to each vaccine administered individually and to licensed meningococcal vaccine Meningitec cent .

 The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

